Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

Abstract β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson’s disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca) and protein (α-syn). Effects of β2AR agonist clenbuterol on the levels of Snca mRNA and α-syn p...

Full description

Bibliographic Details

Published in:	npj Parkinson's Disease
Main Authors:	Joseph R. Patterson, Warren D. Hirst, Jacob W. Howe, Christopher P. Russell, Allyson Cole-Strauss, Christopher J. Kemp, Megan F. Duffy, Jared Lamp, Andrew Umstead, Michael Kubik, Anna C. Stoll, Irving E. Vega, Kathy Steece-Collier, Yi Chen, Anne C. Campbell, Catherine L. Nezich, Kelly E. Glajch, Caryl E. Sortwell
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-05-01
Online Access:	https://doi.org/10.1038/s41531-022-00322-x